Episcleritis in a patient with mucosal melanoma treated with interferon alfa-2b and radiotherapy: a case report

J Med Case Rep. 2018 Dec 23;12(1):388. doi: 10.1186/s13256-018-1913-7.

Abstract

Background: Mucosal melanoma of the head and neck is a rare malignant tumor associated with a poor prognosis. Surgery, chemotherapy, radiotherapy, and biotherapy are common strategies for treating mucosal melanoma of the head and neck. Episcleritis is an idiopathic, immune-mediated disease, and is classified into two types: simple episcleritis and nodular episcleritis.

Case presentation: In this case report we describe ocular changes involving simple episcleritis in a 65-year-old Chinese man with mucosal melanoma of the head and neck after treatment with interferon alfa-2b and radiotherapy. On the third day of interferon alfa-2b treatment, he began to develop simple episcleritis in his left eye. Moreover, the percentage of CD3+ T cells in lymphocytes from blood was increased after interferon alfa-2b treatment. After approximately 6 days, the symptoms of eye pain, hyperemia, and edema disappeared gradually. Then, after radiotherapy was performed three times, he again developed episcleritis in his left eye. The same symptoms of hyperemia and edema occurred again; CD3+ T cell frequency was also at a higher level. After approximately a week, all the symptoms disappeared completely. Simple treatment involving topical ofloxacin and phenylephrine was administered during the two periods of episcleritis.

Conclusion: Episcleritis in this patient might have been due to the treatment with interferon alfa-2b and radiotherapy, leading to an increase in the level of CD3+ T cells and activation of immune system cells, which provides the guide for clinical clinicians.

Keywords: Anti-tumor immunity; Episcleritis; Immune-mediated; Interferon alfa-2b; Mucosal melanoma of the head and neck (MMHN); Radiotherapy; Tumor immunology.

Publication types

  • Case Reports

MeSH terms

  • Aged
  • Anti-Bacterial Agents / therapeutic use
  • Antineoplastic Agents / adverse effects
  • Antineoplastic Agents / therapeutic use*
  • Chemotherapy, Adjuvant
  • Combined Modality Therapy
  • Head and Neck Neoplasms / physiopathology
  • Head and Neck Neoplasms / therapy*
  • Humans
  • Interferon alpha-2 / adverse effects
  • Interferon alpha-2 / therapeutic use*
  • Male
  • Melanoma / physiopathology
  • Melanoma / therapy*
  • Ofloxacin / therapeutic use
  • Ophthalmic Solutions / therapeutic use
  • Phenylephrine / therapeutic use
  • Radiotherapy* / adverse effects
  • Treatment Outcome

Substances

  • Anti-Bacterial Agents
  • Antineoplastic Agents
  • Interferon alpha-2
  • Ophthalmic Solutions
  • Phenylephrine
  • Ofloxacin